<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646009</url>
  </required_header>
  <id_info>
    <org_study_id>SD-039-0733</org_study_id>
    <secondary_id>D5896C00733</secondary_id>
    <nct_id>NCT00646009</nct_id>
  </id_info>
  <brief_title>Symbicort Onset of Action 2</brief_title>
  <official_title>A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the early onset of effect of Symbicort compared to
      Advair Diskus and Ventolin in adults with asthma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 3 minutes post dose</measure>
    <time_frame>4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 hour serial FEV1</measure>
    <time_frame>4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients perception of effect</measure>
    <time_frame>Patients perception of effect</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>budesonide/formoterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluticasone/salmeterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>albuterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Symbicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone/salmeterol</intervention_name>
    <arm_group_label>2</arm_group_label>
    <other_name>Advair Diskus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol</intervention_name>
    <arm_group_label>3</arm_group_label>
    <other_name>Ventolin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Diagnosis of asthma and baseline lung function test results as determined by the
             protocol

          -  Required and received inhaled corticosteroids within timeframe and doses specified in
             the protocol

        Exclusion Criteria:

          -  Severe asthma or asthma that is markedly effected by seasonal factors

          -  Has required and received non-inhaled corticosteroids within the previous 4 weeks, has
             sensitivity to drugs specified in the protocol or requires treatment with
             beta-blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Bonuccelli</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <keyword>asthma</keyword>
  <keyword>adults</keyword>
  <keyword>Symbicort</keyword>
  <keyword>budesonide/formoterol</keyword>
  <keyword>Advair Diskus</keyword>
  <keyword>Ventolin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

